Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
ALK upgrades its full-year outlook
Regulatory Filings
2026-05-04 Danish
ALK upgrades its full-year outlook
Regulatory Filings
2026-05-04 Danish
ALK upgrades its full-year outlook
Regulatory Filings
2026-05-04 English
ALK upgrades its full-year outlook
Regulatory Filings
2026-05-04 English
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
Regulatory Filings Classification · 75% confidence The document is a company announcement (Selskabsmeddelelse) disclosing clinical Phase 2 trial results for a peanut allergy tablet and contains “intern viden” under EU market abuse rules. It is not an earnings release, interim or annual report, nor does it relate to board changes, dividends, financing, M&A, or governance. It is a stand‐alone regulatory disclosure of trial data, fitting the fallback category for miscellaneous regulatory announcements.
2026-04-20 Danish
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
Regulatory Filings Classification · 87% confidence The document is a press release announcing positive Phase 2 clinical trial results for ALK’s peanut allergy tablet. It contains no financial results, no shareholder votes, no board changes, and no regulatory form filings such as 10-K or interim reports. Instead, it is a general corporate announcement on product development, which does not fit any specific category. The appropriate fallback category for such miscellaneous corporate announcements is “Regulatory Filings” (RNS).
2026-04-20 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.